Akebia Announces Participation in the Future Leaders in the Biotech Industry Conference
CINCINNATI, OH--(Marketwire - April 06, 2010) - Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that Joseph Gardner, Ph.D., president and chief executive officer will be presenting at the BioCentury and Thomson Reuters Future Leaders in the Biotech Industry Conference. During the presentation, Dr. Gardner will provide an overview of the company including recent product development activities and strategic advancements.
The following are specific details regarding Akebia's presentation at the conference:
BioCentury & Thomson Reuters Future Leaders in the Biotech Industry Conference
Date: April 8, 2010
Time: 10:00 AM
Location: Millennium Broadway Hotel & Conference Center, New York, NY
Room: Presentation Room 311 (Breakout in Room 310 immediately following)
About Akebia Therapeutics
Akebia Therapeutics is a discovery and development company focused on anemia and vascular disorders. Akebia's lead program, AKB-6548, an orally bioavailable HIF-prolyl hydroxylase (HIF-PH) inhibitor for patients with anemia, is in phase 1 clinical trials. AKB-6548 potentially promises to be a safer, less expensive, orally dosed pharmaceutical to stimulate endogenous EPO production. Additionally, Akebia has a novel HPTPbeta inhibitor / Angiopoietin 2 modulator, AKB-9778, for the treatment of vascular leak syndrome and critical limb ischemia which is scheduled to commence phase 1 clinical trials in 2010.
Ian Howes, CFO & V.P. Corporate Development, Akebia Therapeutics, Inc.
513/985-1923, Email Contact
Michelle Linn, Linnden Communications, 508/362-3087, Email Contact